Potential of anticytokine therapies in central nervous system ischaemia
- 1 March 2001
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 1 (2), 227-237
- https://doi.org/10.1517/14712598.1.2.227
Abstract
Central nervous system (CNS) ischaemia is associated with an acute inflammatory response which appears to potentiate CNS injury, especially following reperfusion. This response includes the release of inflammatory mediators called cytokines including IL-1 and TNF-α, which triggers the production of additional cytokines including IL-6 and activates leukocytes which infiltrate into the CNS. Increased expression of cytokines has been demonstrated to occur in the first few hours after CNS ischaemia. Preliminary clinical studies suggest that plasma levels of IL-6 are correlated with functional recovery while brain levels of cytokines have been demonstrated to increase following experimental ischaemia. Although there are no current clinical ‘anti-cytokine’ treatment studies for stroke, experimental studies modulating IL-1 and TNF-α have shown neuroprotection.Keywords
This publication has 50 references indexed in Scilit:
- Novel Homologues of CSBP/p38 MAP Kinase: Activation, Substrate Specificity and Sensitivity to Inhibition by Pyridinyl ImidazolesBiochemical and Biophysical Research Communications, 1997
- Leukocyte Activation Detected by Increased Plasma Levels of Inflammatory Mediators in Patients With Ischemic Cerebrovascular DiseasesStroke, 1996
- Anti–Intercellular Adhesion Molecule–1 Antibody Reduces Ischemic Cell Damage After Transient But Not Permanent Middle Cerebral Artery Occlusion in the Wistar RatStroke, 1995
- Early Intrathecal Production of Interleukin-6 Predicts the Size of Brain Lesion in StrokeStroke, 1995
- Interleukin-1 as a Pathogenetic Mediator of Ischemic Brain Damage in RatsStroke, 1995
- Tumor necrosis factor-alpha expression in ischemic neurons.Stroke, 1994
- Polymorphonuclear leukocytes and monocytes/macrophages in the pathogenesis of cerebral ischemia and stroke.Stroke, 1992
- Reduction of central nervous system ischemic injury in rabbits using leukocyte adhesion antibody treatment.Stroke, 1991
- Interleukin-1 receptor antagonist reduces mortality from endotoxin shockNature, 1990
- In vitro study of mediators of inflammation in multiple sclerosisJournal of Clinical Immunology, 1989